What is Qcdx?
QCDx is a pioneering medical device company dedicated to the early detection of circulating tumor cells (CTCs). Their advanced technology facilitates enrichment-free profiling and isolation of rare CTCs, enabling real-time cancer intelligence through minimally invasive blood tests. This innovative approach aims to revolutionize cancer diagnosis by optimizing treatment strategies, monitoring therapeutic efficacy, and assessing treatment toxicity, ultimately enhancing patient outcomes and quality of life. The company's solutions are designed for oncologists and the pharmaceutical industry, supporting critical cancer research and drug discovery initiatives across all disease stages.
How much funding has Qcdx raised?
Qcdx has raised a total of $7M across 2 funding rounds:
Debt
$14K
Other Financing Round
$7M
Debt (2021): $14K with participation from PPP
Other Financing Round (2025): $7M, investors not publicly disclosed
What's next for Qcdx?
With the recent major strategic investment, Qcdx is poised for significant expansion and further development of its groundbreaking CTC detection technology. This capital will likely fuel advancements in product refinement, clinical validation, and market penetration, solidifying its position in the competitive landscape of precision oncology diagnostics. The company's focus on early detection and real-time cancer intelligence suggests a trajectory towards becoming a key player in personalized medicine, offering critical insights for treatment planning and patient monitoring.
See full Qcdx company page
